December 4 & 11, 2026

Conference Agenda

  Download Agenda PDF
December 4 December 11
Agenda: : Friday, December 04, 2026
Time Topic Speaker(s)
12:00 PM Welcome & Introduction
12:08 PM Keynote Address: Are we treating obesity or reengineering metabolism?

At the conclusion of this activity participants will be able to:

  • Evaluate how obesity treatments influence metabolic health beyond weight reduction, including effects on glycemic control and cardiometabolic risk.
 TBC
12:40 PM Theme One Introductions 
12:43 PM Adipose tissue diversity: function and malfunction

At the conclusion of this activity participants will be able to:

  • Explain how differences in adipose tissue distribution and function contribute to obesity-related metabolic complications.
 Guillaume Pare
01:01 PM What do the latest dietary guidelines teach us?

At the conclusion of this activity participants will be able to:

  • Apply current Canadian and U.S. dietary guidance to develop individualized, sustainable nutrition recommendations for adults living with obesity.
 TBC
01:19 PM Physical activity recommendations

At the conclusion of this activity participants will be able to:

  • Apply evidence-based physical activity recommendations to support individualized obesity management.
 TBC
01:55 PM Theme Two Introductions 
01:58 PM How do current treatments stack up for weight loss and diabetes management?

At the conclusion of this activity participants will be able to:

  • Compare the efficacy, safety, and patient-selection considerations of current obesity treatments for weight management and glycemic control.
 TBC
02:16 PM Muscle loss - reality or hype?

At the conclusion of this activity participants will be able to:

  • Evaluate evidence on changes in lean mass and muscle function during obesity treatment and identify strategies to preserve physical function.
 TBC
02:34 PM Nutritional deficiencies with long-term treatment

At the conclusion of this activity participants will be able to:

  • Identify potential nutritional deficiencies associated with long-term obesity treatments and appropriate strategies for assessment, prevention, and management.
 TBC
03:10 PM REFRESHMENT BREAK
03:35 PM Theme Three Introductions
03:38 PM When obesity is a symptom: early recognition of genetic obesity 

At the conclusion of this activity participants will be able to:

  • Recognize clinical features, including early-onset obesity, hyperphagia, and multisystem findings, that warrant evaluation or referral for rare genetic obesity.
 Sue Pedersen
03:56 PM Sleep and obesity

At the conclusion of this activity participants will be able to:

  • Identify obstructive sleep apnea in patients living with obesity and discuss practical approaches to diagnosis and management.
04:14 PM MASLD and more: diagnosis and management

At the conclusion of this activity participants will be able to:

  • Apply a risk-based approach to identifying, assessing, and managing metabolic dysfunction-associated steatotic liver disease (MASLD) in patients living with obesity.
 Ellina Lytyvak
04:50 PM DEBATE: GLP1/Bariatric Surgery: Competitors or Collaborators?
04:53 PM GLP-1s will replace bariatric surgery

At the conclusion of this activity participants will be able to:

  • Evaluate evidence supporting the use of incretin-based pharmacotherapy as an alternative to bariatric surgery for selected patients with obesity.
 TBC
05:13 PM GLP-1s will complement bariatric surgery

At the conclusion of this activity participants will be able to:

  • Identify clinical circumstances in which incretin-based pharmacotherapy and bariatric surgery may be used sequentially or together to support long-term obesity care.
 TBC
05:33 PM Discussion
05:45 PM Meeting Close
Agenda: : Friday, December 11, 2026
Time Topic Speaker(s)
12:00 PM Welcome & Introduction
12:08 PM KeyNote Address: Precision medicine for obesity

At the conclusion of this activity participants will be able to:

  • Evaluate how clinical phenotype, complications, treatment response, and patient preferences can guide individualized obesity treatment selection.
 Andreas Acosta
12:40 PM Theme One Introductions
12:43 PM Successful global food policies

At the conclusion of this activity participants will be able to:

  • Assess the effects and limitations of food-policy interventions on dietary behaviours, obesity prevention, and population health across different settings.
 TBC
01:01 PM What to do when GLP-1's are not accessible?

At the conclusion of this activity participants will be able to:

  • Develop evidence-based obesity management plans when GLP-1 receptor agonists are inaccessible, incorporating alternative therapies, behavioural support, and available resources.
 TBC
01:19 PM Where do generics fit in?

At the conclusion of this activity participants will be able to:

  • Evaluate the potential role of generic medications in improving access to obesity treatment.
 TBC
01:55 PM Theme Two Introductions
01:58 PM ASCVD

At the conclusion of this activity participants will be able to:

  • Integrate obesity management into atherosclerotic cardiovascular disease (ASCVD) risk reduction using evidence on lifestyle, pharmacologic, and procedural interventions.
 Neha Pagidipati
02:16 PM Chronic Kidney Disease

At the conclusion of this activity participants will be able to:

  • Identify evidence-based strategies for managing obesity in patients with chronic kidney disease to improve clinical outcomes.
 David Cherney
02:34 PM Heart Failure

At the conclusion of this activity participants will be able to:

  • Evaluate obesity treatment options in patients with heart failure, considering heart failure phenotype, clinical outcomes, and treatment safety.
 TBC
03:10 PM REFRESHMENT BREAK
03:35 PM Theme Three Introductions 
03:38 PM GLP-1's: Current and future agents

At the conclusion of this activity participants will be able to:

  • Compare the efficacy, safety, and clinical applications of current and emerging oral and injectable GLP-1 receptor agonists in obesity management.
 TBC
03:56 PM Dual agonists: Current and future agents

At the conclusion of this activity participants will be able to:

  • Compare current and emerging dual-agonist therapies for obesity, including their mechanisms, clinical evidence, safety profiles, and potential patient selection.
 TBC
04:14 PM Triple agonists and beyond

At the conclusion of this activity participants will be able to:

  • Evaluate emerging multi-target therapies for obesity, including their clinical evidence and remaining gaps in research.
 TBC
04:50 PM DEBATE - Should we initiate GLP-1s before patients develop comorbidities?
04:53 PM Patients should be started early based on BMI/obesity thresholds

At the conclusion of this activity participants will be able to:

  • Appraise evidence supporting initiation of GLP-1 receptor agonist therapy before obesity-related complications develop, including eligibility criteria and potential long-term benefits and risks.
 TBC
05:13 PM Not all patients with obesity need treatment: wait for comorbidities

At the conclusion of this activity participants will be able to:

  • Appraise evidence supporting complication-based selection and timing of GLP-1 receptor agonist therapy, including risks, benefits, and the role of nonpharmacologic management.
 TBC
05:45 PM Meeting Close